StockStory.org on MSN14h
10x Genomics (NASDAQ:TXG) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses ExpectationsBiotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback